Quick Search
Products Alzheimer Product Line
Since it was first described by Alois Alzheimer in 1906, Alzheimer´s Disease (AD) has become an increasing burden on the world´s aging population. Some 26 million people worldwide are currently estimated to suffer from it, and the number is expected to grow significantly by 2050.
IBL international provides the AD research community with parameters for research into neurodegenerative diseases for the determination of Amyloid-beta, A-beta fragments and the Amyloid precursor APP. Specialties include Prion Protein or LRG (leucine-rich alpha-2-glycoprotein for iNPH).
Get the Best Promotions
